LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Aardvark Therapeutics, Inc., (“Aardvark” or the “Company”) (NASDAQ: AARD) investors of a class action on behalf of investors that bought securities between February 13, 2025 and May 14, 2026, inclusive (the “Class Period”). Aardvark investors have until October 13, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/aardvark-therapeutics-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The plaintiff alleges that the Offering Documents that were filed in the Company’s February 13, 2025 initial public offering (“IPO”) and that between February 13, 2025 and May 14, 2026 the Defendants made false and/or misleading statements and/or failed to disclose that ARD-101 was less safe than the Defendants had led investors to believe, that accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated, and that as a result, the Defendants’ public statements were materially false and misleading at all relevant times.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

About The Author
Portnoy Law